Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

35.87 +0.60 (+1.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
2 Surging Stocks to Research Further and 1 to Be Wary Of
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds
Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch. 
Via Benzinga
Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma
Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured... 
Via Stocktwits
A Look Into Royalty Pharma Inc's Price Over Earnings
Via Benzinga
How Is The Market Feeling About Royalty Pharma?
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
Peering Into Royalty Pharma's Recent Short Interest
Via Benzinga
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $568.2 million. Its non-GAAP EPS of $1.06 per share was... 
Via StockStory
2 Value Stocks to Target This Week and 1 to Turn Down
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
1 Stock Under $50 with Competitive Advantages and 2 to Question
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
3 of Wall Street’s Favorite Stocks with Mounting Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share... 
Via StockStory
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors
Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors 
Via Chartmill
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Technical Analysis observations.
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout. 
Via Chartmill
3 Mid-Cap Stocks Facing Headwinds
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
Topics Economy
Omnicell, Royalty Pharma, EXL, IMAX, and OPENLANE Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%,... 
Via StockStory
Topics Economy Government World Trade
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
4 Healthcare Stocks With Massive Gains—and More to Come
Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year. 
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
3 Reasons to Sell RPRX and 1 Stock to Buy Instead
Over the past six months, Royalty Pharma has been a great trade. While the S&P 500 was flat, the stock price has climbed by 17.3% to $33.06 per share. This performance may have investors wondering how... 
Via StockStory
Topics Stocks
The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry
In this video lesson, I review the overall market and a new swing position for Monday's session. 
Via Talk Markets
Topics ETFs Stocks / Equities
Uncovering Noteworthy Technical Analysis Findings for ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX).
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout. 
Via Chartmill
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
3 Value Stocks in Hot Water
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
How Do Investors Really Feel About Royalty Pharma?
Via Benzinga
Is ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Ready to Break Out of Its Range?
Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Based on good technical signals, ROYALTY PHARMA PLC- CL A is potentially setting up for a breakout. 
Via Chartmill
1 Stock Under $50 with Exciting Potential and 2 to Ignore
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.